Device Trial Radar · NCT07005063
Rotator Cuff Tendon Repair With FiberLocker System Patch Augmentation
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Jul 3, 2025
Primary completion
Jun 30, 2029
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- ZuriMED Technologies AGNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 4, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of this clinical investigation is to assess the safety and efficacy of full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System for the subjects. The primary outcome of the investigation is to assess the safety after full-thickness arthroscopic rotator cuff repairs augmented with the FiberLocker System in terms of postoperative adverse events through the 12-month follow-up. Main secondary outcomes include measures of efficacy and clinical performance evaluated at 6-week, 4.5-month, and 12-month follow-ups including retear rate assessed using MRI and different functional performance scores.
Conditions
- Rotator Cuff Tear
- Rotator Cuff Injury
- Rotator Cuff Rupture
Interventions
FiberLocker® System (encompassing SpeedPatch® PET and FiberLocker Instrument® SN)Device
The FiberLocker® System is a mechanical augmentation system that includes an implant (SpeedPatch® PET) and an instrument (FiberLocker® Instrument SN) for its attachment. The implant is composed of non-woven PET fibers, and the instrument features a reciprocating needle at its tip, which pushes the individual patch fibers into the underlying tendon tissue
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Number of Adverse Events (AEs)Time frame: Surgery to 12-month follow-up
5 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Balgrist University Hospital
Zurich, Canton of Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.